

Dr. Reddy's announces the launch of Ziprasidone Mesylate

17 March 2020 | News

It is the therapeutic generic equivalent of Geodon



Dr. Reddy's Laboratories has announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection, 20 mg/mL, approved by USFDA.

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories said, "We're pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy. This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment."

The Geodon® brand had U.S. sales of approximately \$21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.